AC
CALA

Ascend Capital’s Calithera Biosciences, Inc CALA Stock Holding History

Ascend Capital’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$138K Sell
1,321
-10,084
-88% -$960K 0.01% 163
2018
Q2 		$1.14M Sell
11,405
-15,372
-57% -$1.74M 0.05% 154
2018
Q1 		$3.37M Sell
26,777
-7,913
-23% -$1.23M 0.14% 139
2017
Q4 		$5.79M Buy
34,690
+1,780
+5% +$456K 0.22% 108
2017
Q3 		$10.4M Buy
32,910
+12,230
+59% +$3.86M 0.39% 78
2017
Q2 		$6.14M Buy
+20,680
New +$5.53M 0.29% 97

Other funds holding CALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ascend Capital's CALA Position: Q3 2018 in Review

Ascend Capital reduced its Calithera Biosciences, Inc (CALA) stake by 88% in Q3 2018, selling an estimated $960K and leaving 1,321 shares worth $138K. The position accounts for 0.01% of the portfolio, ranked #163.

Ascend Capital first reported a position in CALA in Q2 2017 and has held it in 6 quarters since. The position peaked at $10.4M in Q3 2017. 81 funds tracked by Wall St. Rank hold CALA as of Q3 2018.

  • Ascend Capital held 1,321 shares of Calithera Biosciences, Inc worth $138K as of Q3 2018.
  • Ascend Capital sold 10,084 Calithera Biosciences, Inc shares in Q3 2018, an estimated $960K.
  • Calithera Biosciences, Inc made up 0.01% of Ascend Capital's portfolio in Q3 2018, its #163 holding.
  • Ascend Capital first reported a position in Calithera Biosciences, Inc in Q2 2017 and has held it in 6 quarters since.
  • Ascend Capital's Calithera Biosciences, Inc position peaked at $10.4M in Q3 2017.
  • 81 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.